TABLE 1.
Demographic details of 227 subjects: 106 control and 121 individuals with biopsy‐proven NAFLD stratified by fibrosis stage (F0‐2 vs F3‐4)
| Control | F0‐2 | F3‐4 | P‐value | |
|---|---|---|---|---|
| N (m/f) (males, %) | 106 (41/65) (38.7) | 39 (20/19) (51.3) | 82 (39/43) (47.6) | 0.29 |
| Age, y | 55.5 ± 11.1 | 45.6 ± 12.0* | 61.8 ± 10.8*,** | <0.0001 |
| BMI, kg/m2 | 30.7 ± 5.8 | 38.5 ± 7.0* | 33.7 ± 5.8*,** | <0.0001 |
| Proportion with type 2 diabetes, % | 3.8 | 30.8* | 63.4*,** | <0.0001 |
| HbA1c, mmol/mol | 38.6 ± 10.4 | 40.8 ± 8.2 | 50.0 ± 13.5*,** | <0.0001 |
| Platelets, 10 y2/L | n/a | 242.5 ± 64.2 | 183.9 ± 67.0** | <0.0001 |
| ALT, IU/L | 13.2 ± 8.7 | 63.4 ± 51.4* | 49.9 ± 36.9* | <0.0001 |
| AST, IU/L | n/a | 34.4 ± 22.0 | 49.1 ± 31.8** | 0.0006 |
| Fib‐4 score | n/a | 0.931 ± 0.7 | 2.61 ± 1.7** | <0.0001 |
| NAFLD fibrosis score | n/a | 1.9 ± 1.2 | 3.8 ± 1.6** | <0.0001 |
| NAS score (0‐8) | n/a | 4.0 ± 1.7 | 4.7 ± 1.3** | 0.029 |
| Proportion with NAS score ≥5, % | n/a | 42.1 | 63.1 | 0.07 |
Data expressed are mean ± standard deviation (unless otherwise stated). Where applicable, P‐value stated in the final column is the summary ANOVA value when all three groups are compared (*P < 0.05 vs control; **P < 0.05 vs F0‐2).
Abbreviations: BMI, body mass index; FIB‐4, fibrosis‐4 score; NAFLD, non‐alcoholic fatty liver disease; NAS, NAFLD Activity Score.